Back to Journals » Cancer Management and Research » Volume 12

High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab

Authors Jiang L, Fang J, Ding J

Received 17 September 2019

Accepted for publication 24 December 2019

Published 21 January 2020 Volume 2020:12 Pages 475—484

DOI https://doi.org/10.2147/CMAR.S231444

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Ahmet Emre Eskazan


Li Jiang, 1, 2 Jianjiang Fang, 2 Jinhua Ding 3

1Department of General Practice, Ningbo Medical Center Lihuili Hospital/Taipei Medical University Ningbo Medical Center, Ningbo, Zhejiang 315000, People’s Republic of China; 2Department of Emergency, Ningbo Medical Center Lihuili Hospital/Taipei Medical University Ningbo Medical Center, Ningbo, Zhejiang 315000, People’s Republic of China; 3Department of Breast and Thyroid Surgery, Ningbo Medical Center Lihuili Hospital/Taipei Medical University Ningbo Medical Center, Ningbo, Zhejiang 315000, People’s Republic of China

Correspondence: Jinhua Ding
Tel +86 574 5583 6143
Email cookie800128@sina.com

Purpose: Neutrophils and platelets have been described as tumor-promoting factors, but lymphocytes have been described as tumor-inhibiting factors. The prognostic values of the neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) have been explored in human epidermal growth factor receptor (HER2)-positive breast cancer, however, the value of the systemic immune- inflammation index (SII) has not been studied in this molecular subtype. Our study aimed to compare the prognostic values of these inflammation-based indexes in Chinese HER2-positive breast cancer patients who received adjuvant trastuzumab.
Methods: A total of 147 HER2-positive breast cancer patients were retrospectively analyzed. The association between clinicopathological factors and inflammation-based indexes was investigated. The Kaplan-Meier method was used to evaluate overall survival (OS) and disease-free survival (DFS); the Log rank test was performed to comparatively evaluate the survivals between the high-value and low-value groups. Multivariate Cox regression analysis was used to identify independent prognostic factors.
Results: The SII value correlated significantly with histological grade (HG)(p=0.016). The cut-off values determined by ROC analysis for the NLR, PLR and SII were 1.69, 110 and 442, and the corresponding areas under the curves (AUCs) were 0.621, 0.639 and 0.674, respectively. The 5-year DFS was significantly lower in the NLR-high than in the NLR-low group (75.8% vs. 90.7%, p< 0.01), in the PLR-high than in the PLR-low group (76.7% vs. 90.6%, p< 0.01) and in the SII-high than in the SII-low group (66.8% vs. 90.7%, p< 0.01). The 5-year OS was significantly lower in the PLR-high than in the PLR-low group (83.2% vs. 100%, p=0.035) and in the SII-high than in the SII-low group (77.3% vs. 96.4%, p=0.012). A multivariate regression model revealed that tumor size, lymph node involvement, HG, hormone receptor status, PLR and SII were independently correlated with DFS; lymph node involvement and SII were independently correlated with OS.
Conclusion: Our study suggests that SII is an independent prognostic factor for DFS and OS in HER2-positive breast cancer, and in terms of prognostic reliability, the SII is superior to other inflammation-based indexes.

Keywords: breast cancer, HER2, NLR, PLR, SII, prognosis


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]